Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 156.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,221 shares of the medical research company's stock after buying an additional 1,966 shares during the quarter. SG Americas Securities LLC's holdings in Bio-Rad Laboratories were worth $1,058,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of BIO. Principal Financial Group Inc. boosted its holdings in Bio-Rad Laboratories by 95.6% during the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company's stock valued at $14,836,000 after acquiring an additional 21,669 shares during the period. Mawer Investment Management Ltd. grew its holdings in shares of Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock worth $72,900,000 after purchasing an additional 84,237 shares during the last quarter. Verition Fund Management LLC increased its stake in Bio-Rad Laboratories by 193.3% in the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company's stock worth $1,161,000 after buying an additional 2,287 shares during the period. Diversified Trust Co bought a new stake in Bio-Rad Laboratories during the 4th quarter valued at about $958,000. Finally, Louisiana State Employees Retirement System boosted its position in Bio-Rad Laboratories by 341.7% in the 3rd quarter. Louisiana State Employees Retirement System now owns 5,300 shares of the medical research company's stock valued at $1,773,000 after buying an additional 4,100 shares during the period. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Down 3.3 %

BIO traded down $12.03 on Wednesday, hitting $354.97. The company had a trading volume of 140,528 shares, compared to its average volume of 153,363. The stock has a market capitalization of $9.94 billion, a price-to-earnings ratio of -12.99 and a beta of 0.90. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The stock has a fifty day moving average price of $338.42 and a 200-day moving average price of $334.32. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company's quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.33 EPS. Analysts predict that Bio-Rad Laboratories, Inc. will post 10.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Citigroup lifted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $394.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.